Detection of HER2 amplification in circulating free DNA in patients with breast cancer

British Journal of Cancer

Volumn 104, Issue 8, 2011, Pages 1342-1348

  Page, K ^a   Hava, N ^b   Ward, B ^b   Brown, J ^a   Guttery, D S ^a   Ruangpratheep, C ^a   Blighe, K ^a   Sharma, A ^c   Walker, R A ^a   Coombes, R C ^b   Shaw, J A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

breast cancer; HER2 amplification; quantitative PCR; tumour markers

Indexed keywords

CONTACTIN ASSOCIATED PROTEIN 1; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VALIDATION PROCESS;

BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; NEOPLASM METASTASIS; PHENOTYPE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 79954431896     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.89     Document Type: Article

References (30)

1. Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG (2001) Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195: 422-428 (Pubitemid 33069666)
2. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61: 1890-1895 (Pubitemid 32692004)
3. Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D (2006) Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5: 2572-2579 (Pubitemid 44650922)
4. Davis G, Davis JS (1973) Detection of circulating DNA by counter immunoelectrophoresis (CIE). Arthritis Rheum 16: 52-55
5. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane N, Solomayer E, Uhr J (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9: R74
6. Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124: 403-412
7. Goebel G, Zitt M, Zitt M, Müller HM (2005) Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21: 105-120 (Pubitemid 41566728)
8. Koffler D, Agnello V, Winchester R, Kunkel H (1973) The occurrence of single stranded DNA in the serum of patients with SLE and other diseases. J Clin Invest 52: 198-204
9. Kulka J, Tokes AM, Kaposi-Novak P, Udvarhelyi N, Keller A, Schaff Z (2006) Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immuno-histochemical and FISH results. Pathol Oncol Res 12: 197-204
10. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U (2001) Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19: 354-363 (Pubitemid 32112846)
11. Leon SA, Revach M, Ehrlich GE, Adler R, Petersen V, Shapiro B (1981) DNA in synovial fluid and the circulation of patients with arthritis. Arthritis Rheum 24: 1142-1150 (Pubitemid 11057341)
12. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101: 9393-9398 (Pubitemid 38812885)
13. Monego G, Arena V, Maggiano N, Costarelli L, Crescenzi A, Zelano G, Amini M, Capelli A, Carbone A (2007) Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values. Scand J Clin Lab Invest 67: 402-412 (Pubitemid 46897614)
14. Page K, Powles T, Slade MJ, MT DEB, Walker RA, Coombes RC, Shaw JA (2006) The importance of careful blood processing in isolation of cell-free DNA. Ann NY Acad Sci 1075: 313-317 (Pubitemid 44532799)
15. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of methods for tissue-based detection of the HER-2/ neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18: 3651-3664
16. Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52: 65-77 (Pubitemid 29056086)
17. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3: 237-252
18. Shaw JA, Brown J, Coombes RC, Jacob J, Payne R, Lee B, Page K, Hava N, Stebbing J (2011) Circulating tumour cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. Biomark Med 5: 87-91
19. Slade MJ, Payne R, Riethdorf S, Ward B, Zaidi SA, Stebbing J, Palmieri C, Sinnett HD, Kulinskaya E, Pitfield T, McCormack RT, Pantel K, Coombes RC (2009) Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer 100: 160-166
20. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182 (Pubitemid 17231334)
21. Sorensen BS, Mortensen LS, Andersen J, Nexo E (2010) Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. Anticancer Res 30: 2463-2468
22. Suo Z, Daehli KU, Lindboe CF, Borgen E, Bassarova A, Nesland JM (2004) Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients. Int J Surg Pathol 12: 311-318 (Pubitemid 39463500)
23. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212
24. van der Vaart M, Pretorius PJ (2008) Circulating DNA. Its origin and fluctuation. Ann NY Acad Sci 1137: 18-26
25. van der Vaart M, Pretorius PJ (2010) Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 43: 26-36
26. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239-1245 (Pubitemid 18267063)
27. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ (2001) First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61(Suppl 2): 37-42 (Pubitemid 33033423)
28. Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM, Jasani B, Miller K, Pinder SE (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61: 818-824 (Pubitemid 351969725)
29. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12: 1715-1720
30. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A (2005) Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552-556 (Pubitemid 43079998)